123 related articles for article (PubMed ID: 38015431)
1. Factors influencing treatment response of pulmonary exacerbation in children with cystic fibrosis.
Singh J; Robinson P; Pandit C; Kennedy B; Weldon B; Bailey B; John M; Fitzgerald D; Selvadurai H
Minerva Pediatr (Torino); 2024 Apr; 76(2):245-252. PubMed ID: 38015431
[TBL] [Abstract][Full Text] [Related]
2. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Sanders DB; Hoffman LR; Emerson J; Gibson RL; Rosenfeld M; Redding GJ; Goss CH
Pediatr Pulmonol; 2010 Feb; 45(2):127-34. PubMed ID: 20054859
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
4. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.
Waters V; Stanojevic S; Atenafu EG; Lu A; Yau Y; Tullis E; Ratjen F
Eur Respir J; 2012 Jul; 40(1):61-6. PubMed ID: 22135280
[TBL] [Abstract][Full Text] [Related]
5. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F
J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
Sanders DB; Bittner RC; Rosenfeld M; Redding GJ; Goss CH
Pediatr Pulmonol; 2011 Apr; 46(4):393-400. PubMed ID: 20967845
[TBL] [Abstract][Full Text] [Related]
7. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Amadori A; Antonelli A; Balteri I; Schreiber A; Bugiani M; De Rose V
Respir Med; 2009 Mar; 103(3):407-13. PubMed ID: 19027279
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?
Kapur N; Masters IB; Chang AB
Chest; 2010 Jul; 138(1):158-64. PubMed ID: 20173055
[TBL] [Abstract][Full Text] [Related]
9. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
Sanders DB; Bittner RC; Rosenfeld M; Hoffman LR; Redding GJ; Goss CH
Am J Respir Crit Care Med; 2010 Sep; 182(5):627-32. PubMed ID: 20463179
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry.
Zemel BS; Jawad AF; FitzSimmons S; Stallings VA
J Pediatr; 2000 Sep; 137(3):374-80. PubMed ID: 10969263
[TBL] [Abstract][Full Text] [Related]
11. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
Morgan WJ; Wagener JS; Yegin A; Pasta DJ; Millar SJ; Konstan MW; ;
J Pediatr; 2013 Oct; 163(4):1152-7.e2. PubMed ID: 23810128
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
[TBL] [Abstract][Full Text] [Related]
13. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
14. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Southern KW; Solis-Moya A; Kurz D; Smith S
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
[TBL] [Abstract][Full Text] [Related]
15. Association of the three-minute step test with the occurrence of pulmonary exacerbations in children with cystic fibrosis: a cross-sectional study.
DA Costa GA; Vendrusculo FM; Lemes BM; Damasceno GF; de Oliveira LC; da S Aquino E; Donadio MV
Minerva Pediatr (Torino); 2023 Oct; ():. PubMed ID: 37796060
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis.
Peterson ML; Jacobs DR; Milla CE
Pediatrics; 2003 Sep; 112(3 Pt 1):588-92. PubMed ID: 12949289
[TBL] [Abstract][Full Text] [Related]
17. Increased rate of lung function decline in Australian adolescents with cystic fibrosis.
Welsh L; Robertson CF; Ranganathan SC
Pediatr Pulmonol; 2014 Sep; 49(9):873-7. PubMed ID: 24178906
[TBL] [Abstract][Full Text] [Related]
18. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE; Schechter MS; Wagener JS; Morgan WJ; Pasta DJ; Elkin EP; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):649-57. PubMed ID: 22949088
[TBL] [Abstract][Full Text] [Related]
20. Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.
Sanders DB; Rosenfeld M; Mayer-Hamblett N; Stamey D; Redding GJ
Pediatr Pulmonol; 2008 Nov; 43(11):1142-1146. PubMed ID: 18846562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
